Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    March 2023
  1. YAMASHITA SN, Tanaka Y, Kitagawa T, Baron B, et al
    Down-regulating Effect of a Standardized Extract of Cultured Lentinula edodes mycelia on Cortactin in Prostate Cancer Cells Is Dependent on Malignant Potential.
    Anticancer Res. 2023;43:1159-1166.
    PubMed     Abstract available

  2. NAKAGAWA R, Iwamoto H, Naito R, Kadomoto S, et al
    Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
    Anticancer Res. 2023;43:1351-1359.
    PubMed     Abstract available

    January 2023
  3. TACHIBANA A, Hori S, Nakai Y, Miyake M, et al
    Effects on Life Expectancy of Treatment Decisions in Patients With Non-metastatic Prostate Cancer.
    Anticancer Res. 2023;43:473-483.
    PubMed     Abstract available

  4. DE CICCO L, Marzoli L, Lorusso R, Mancuso RM, et al
    CBCT-based Prostate IGRT With and Without Implanted Markers: Assessment of Geometric Corrections and Time for Completion.
    Anticancer Res. 2023;43:405-408.
    PubMed     Abstract available

  5. FURINI HH, Fukushima KSSQ, DE Nobrega M, DE Souza MF, et al
    An MGMT Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients.
    Anticancer Res. 2023;43:369-379.
    PubMed     Abstract available

  6. NASCIMENTO-GONCALVES E, Seixas F, DA Costa RMG, Pires MJ, et al
    Appraising Animal Models of Prostate Cancer for Translational Research: Future Directions.
    Anticancer Res. 2023;43:275-281.
    PubMed     Abstract available

  7. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:429-436.
    PubMed     Abstract available

  8. PALUMBO I, Ruggiero C, Festa E, DE Fano M, et al
    Bone Health Care Pathway for Non-metastatic Prostate Cancer Patients on Radiation and Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:493-499.
    PubMed     Abstract available

  9. XIAO H, Wu Z, Wang Q, Zhou C, et al
    Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
    Anticancer Res. 2023;43:389-403.
    PubMed     Abstract available

  10. DELL'ATTI L, Aguiari G
    The Role of Genetic Polymorphisms in the Diagnosis and Management of Prostate Cancer: An Update.
    Anticancer Res. 2023;43:317-322.
    PubMed     Abstract available

  11. LIAO CH, Chang WS, Hsu WL, Hu PS, et al
    Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:381-387.
    PubMed     Abstract available

  12. FERDA J, Hes O, Hora M, Ferdova E, et al
    Assessment of Prostate Carcinoma Aggressiveness: Relation to (68)Ga-PSMA-11-PET/MRI and Gleason Score.
    Anticancer Res. 2023;43:449-453.
    PubMed     Abstract available

  13. CHANG LW, Wang SS, Yang CK, Lu K, et al
    Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
    Anticancer Res. 2023;43:485-491.
    PubMed     Abstract available

  14. YAMAMICHI G, Kato T, Uemura M, Nonomura N, et al
    Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers.
    Anticancer Res. 2023;43:283-290.
    PubMed     Abstract available

  15. YE L, Sanders AJ, Jiang WG
    Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer.
    Anticancer Res. 2023;43:291-296.
    PubMed     Abstract available

  16. LI K, Luan Q, Zheng J, Li R, et al
    Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
    Anticancer Res. 2023;43:441-447.
    PubMed     Abstract available

  17. NEUBERGER M, Frey L, Nitschke K, Wessels F, et al
    Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory In Silico Analysis.
    Anticancer Res. 2023;43:417-428.
    PubMed     Abstract available

  18. VALERIO MR, Serretta V, Arico D, Fazio I, et al
    A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer.
    Anticancer Res. 2023;43:501-508.
    PubMed     Abstract available

    Radiotherapy in Prostate Brain Metastases: A Review of the Literature.
    Anticancer Res. 2023;43:311-315.
    PubMed     Abstract available

  20. SUCKOW MA, Hiles MC
    Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
    Anticancer Res. 2023;43:335-341.
    PubMed     Abstract available

  21. LI PH, Liao CH, Huang WC, Chang WS, et al
    Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:343-349.
    PubMed     Abstract available

  22. LEECH M, Leijenaar RTH, Hompland T, Gaffney J, et al
    Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring.
    Anticancer Res. 2023;43:351-357.
    PubMed     Abstract available

  23. MASUDA H
    Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:305-309.
    PubMed     Abstract available

  24. FIALA O, Hosek P, Korunkova H, Hora M, et al
    Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
    Anticancer Res. 2023;43:463-471.
    PubMed     Abstract available

  25. FAUSTINO-ROCHA AI, Jota-Baptista C, Nascimento-Goncalves E, Oliveira PA, et al
    Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies.
    Anticancer Res. 2023;43:323-333.
    PubMed     Abstract available

  26. COLBOURNE JRM, Toniolo JT, Diacon A, Lawrentschuk N, et al
    Following the Trend: A Comparative Analysis of Public Engagement and Funding for Annual Prostate and Breast Cancer Campaigns Using Google Trends.
    Anticancer Res. 2023;43:409-415.
    PubMed     Abstract available

  27. MARTINO T, DE Bem GF, Santos SVM, Coelho MGP, et al
    LQB-118 Suppresses Migration and Invasion of Prostate Cancer Cells by Modulating the Akt/GSK3beta Pathway and MMP-9/Reck Gene Expression.
    Anticancer Res. 2023;43:359-367.
    PubMed     Abstract available

  28. LEHRER S, Rheinstein PH
    Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
    Anticancer Res. 2023;43:437-440.
    PubMed     Abstract available

  29. SCIALPI M, Martorana E, Scialpi P, Scalera GB, et al
    S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence.
    Anticancer Res. 2023;43:297-303.
    PubMed     Abstract available

    November 2022
  30. TAMURA M, Ueda Y, Fukunaga JI, Kamima T, et al
    Impact of Knowledge-based Plan Model Improvement on Plan Complexity and Deliverability in VMAT For Prostate Cancer: A Multi-institutional Study.
    Anticancer Res. 2022;42:5305-5314.
    PubMed     Abstract available

    October 2022
  31. LI JR, Wang SS, Chen CS, Yang CK, et al
    Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Anticancer Res. 2022;42:4857-4866.
    PubMed     Abstract available

  32. OKABE KO, Terada N, Shirakawa T, Onizuka C, et al
    Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
    Anticancer Res. 2022;42:4981-4987.
    PubMed     Abstract available

    July 2022
  33. NAKANISHI E, Hirata T, Tamari K, Isohashi F, et al
    Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged >/=75 Years.
    Anticancer Res. 2022;42:3529-3536.
    PubMed     Abstract available

  34. SHEN YC, Shih HJ, Lin CC, Huang SH, et al
    Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.
    Anticancer Res. 2022;42:3427-3434.
    PubMed     Abstract available

  35. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed     Abstract available

  36. NIEDER C, Stanisavljevic L
    Independent Validation of a Risk Stratification Model Predicting Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:3675-3679.
    PubMed     Abstract available

    June 2022
  37. KAMIJIMA T, Yaegashi H, Mizokami A, Nakajima K, et al
    Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
    Anticancer Res. 2022;42:3099-3108.
    PubMed     Abstract available

  38. PEPE P, Pepe L, Cosentino S, Ippolito M, et al
    Detection Rate of (68)Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer.
    Anticancer Res. 2022;42:3011-3015.
    PubMed     Abstract available

  39. FUJIMOTO N, Minato A, Igawa T, Hiroshige T, et al
    Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Anticancer Res. 2022;42:3041-3047.
    PubMed     Abstract available

  40. PASQUALETTI F, Calistri E, Fuentes T, Sainato A, et al
    Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study.
    Anticancer Res. 2022;42:2997-3001.
    PubMed     Abstract available

    May 2022
  41. REINIKAINEN P, Kapanen M, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer.
    Anticancer Res. 2022;42:2553-2565.
    PubMed     Abstract available

    April 2022
  42. IWAMOTO H, Nakagawa R, Makino T, Kadomoto S, et al
    Treatment Outcomes in Neuroendocrine Prostate Cancer.
    Anticancer Res. 2022;42:2167-2176.
    PubMed     Abstract available

  43. FUJIWARA M, Fujiwara R, Oguchi T, Komai Y, et al
    Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
    Anticancer Res. 2022;42:2123-2130.
    PubMed     Abstract available

  44. NEUBERGER M, Skladny J, Goly N, Wessels F, et al
    Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
    Anticancer Res. 2022;42:1911-1918.
    PubMed     Abstract available

  45. KATSUTA M, Kimura T, Tashiro K, Murakami M, et al
    Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
    Anticancer Res. 2022;42:2023-2028.
    PubMed     Abstract available

    March 2022
  46. PEPE P, Pennisi M
    Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
    Anticancer Res. 2022;42:1495-1498.
    PubMed     Abstract available

  47. MIZOKAMI A, Nishimoto K, Matsuyama H, Ichikawa T, et al
    Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
    Anticancer Res. 2022;42:1465-1475.
    PubMed     Abstract available

  48. LIU C, Zhou Y, Zhou YU, Xu Z, et al
    Kindlin-3 in Immune Cells Is Required to Suppress Prostate Cancer Tumor Growth in Mice.
    Anticancer Res. 2022;42:1217-1220.
    PubMed     Abstract available

    February 2022
  49. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:1107-1114.
    PubMed     Abstract available

  50. SHIMADA T, Izumi K, Kano H, Kadomoto S, et al
    Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
    Anticancer Res. 2022;42:1065-1071.
    PubMed     Abstract available

    January 2022
  51. IACOVELLI R, Ciccarese C, Caffo O, De Giorgi U, et al
    The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:165-172.
    PubMed     Abstract available

  52. LEHTONEN M, Sormunen J, Hjalm-Eriksson M, Thellenberg-Karlsson C, et al
    Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
    Anticancer Res. 2022;42:87-92.
    PubMed     Abstract available

    December 2021
  53. XIE F, Peng F
    Reduction in Copper Uptake and Inhibition of Prostate Cancer Cell Proliferation by Novel Steroid-based Compounds.
    Anticancer Res. 2021;41:5953-5958.
    PubMed     Abstract available

    November 2021
  54. BLAS L, Ieiri K, Shiota M, Nagakawa S, et al
    Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:5593-5598.
    PubMed     Abstract available

    October 2021
  55. KOPELKE S, Bartscht T, Schild SE, Tvilsted S, et al
    Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy.
    Anticancer Res. 2021;41:5165-5169.
    PubMed     Abstract available

  56. TAKAI M, Kawakami K, Fujita Y, Kato T, et al
    Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
    Anticancer Res. 2021;41:4753-4759.
    PubMed     Abstract available

  57. FUJIMOTO N, Harada K, Shiota M, Tomisaki I, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Anticancer Res. 2021;41:4687-4695.
    PubMed     Abstract available

  58. KARLSSON S, Diaz Cruz MA, Faresjo M, Khamou AP, et al
    Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells.
    Anticancer Res. 2021;41:4733-4740.
    PubMed     Abstract available

    September 2021
  59. MASUDA H, Fujimoto A, Kanesaka M, Hou K, et al
    Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Anticancer Res. 2021;41:4443-4446.
    PubMed     Abstract available

  60. MIYATA Y, Masato M, Mukae Y, Nakamura Y, et al
    Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer.
    Anticancer Res. 2021;41:4333-4341.
    PubMed     Abstract available

  61. JACEWICZ M, Rud E, Galtung KF, Noor D, et al
    Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia.
    Anticancer Res. 2021;41:4395-4400.
    PubMed     Abstract available

    August 2021
  62. JIMENEZ ROMERO ME, Gallego MC, Navarro Serrato JC, Sanchez Hurtado MA, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
    Anticancer Res. 2021;41:3955-3968.
    PubMed     Abstract available

  63. BLAS L, Shiota M, Yamada S, Ieiri K, et al
    Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:3885-3889.
    PubMed     Abstract available

  64. WATANABE H, Kawakami A, Sato R, Watanabe K, et al
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Anticancer Res. 2021;41:3753-3758.
    PubMed     Abstract available

  65. OELRICH F, Junker H, Stope MB, Erb HHH, et al
    Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery.
    Anticancer Res. 2021;41:3717-3729.
    PubMed     Abstract available

  66. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available

    July 2021
  67. HARADA J, Miyata Y, Taima T, Matsuda T, et al
    Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.
    Anticancer Res. 2021;41:3327-3335.
    PubMed     Abstract available

  68. ERB HHH, Oster MA, Gelbrich N, Cammann C, et al
    Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Anticancer Res. 2021;41:3271-3279.
    PubMed     Abstract available

    June 2021
  69. PEPE P, Pepe L, Pennisi M, Fraggetta F, et al
    Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
    Anticancer Res. 2021;41:3127-3130.
    PubMed     Abstract available

  70. GARRIDO MM, Ribeiro RM, Kruger K, Pinheiro LC, et al
    Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
    Anticancer Res. 2021;41:3067-3073.
    PubMed     Abstract available

    May 2021
  71. ITO M, Sasamura K, Takase Y, Kotsuma T, et al
    Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
    Anticancer Res. 2021;41:2523-2531.
    PubMed     Abstract available

  72. IINUMA K, Kawakami K, Mizutani K, Fujita Y, et al
    miRNA-93 in Serum Extracellular Vesicles Before and After Low Dose Rate Prostate Brachytherapy.
    Anticancer Res. 2021;41:2411-2418.
    PubMed     Abstract available

    April 2021
  73. SEKITO S, Terabe T, Shibahara T, Onishi T, et al
    Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
    Anticancer Res. 2021;41:2183-2186.
    PubMed     Abstract available

  74. FERINI G, Tripoli A, Molino L, Cacciola A, et al
    How Much Daily Image-guided Volumetric Modulated Arc Therapy Is Useful for Proctitis Prevention With Respect to Static Intensity Modulated Radiotherapy Supported by Topical Medications Among Localized Prostate Cancer Patients?
    Anticancer Res. 2021;41:2101-2110.
    PubMed     Abstract available

  75. HAN Q, Hoffman RM
    Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Anticancer Res. 2021;41:1921-1926.
    PubMed     Abstract available

    March 2021
  76. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.